As of Oct 20
| -0.09 / -1.38%|
The 6 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 15.00 and a low estimate of 12.00. The median estimate represents a +118.41% increase from the last price of 6.41.
The current consensus among 6 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.